PB1120: A long-acting VIP

Like PB1046, PB1120 is a genetic fusion of an analogue of VIP to our ELP biopolymer, but was designed to have similar potency for activation of the VPAC1 and VPAC2 receptors.

PhaseBio is conducting preclinical studies of PB1120 as a potential disease-modifying agent in cystic fibrosis. We also plan to explore PB1120 in other diseases in which VPAC1 agonist activity may be beneficial.